GPR56 Antikörper (PE-Cy7)

Produktnummer ABIN2659352

Dieses Anti-GPR56-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von GPR56 in FACS. Geeignet für Human.

Kurzübersicht für GPR56 Antikörper (PE-Cy7) (ABIN2659352)

Target: GPR56 (G Protein-Coupled Receptor 56 (GPR56))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser GPR56 Antikörper ist konjugiert mit PE-Cy7

Applikation: Flow Cytometry (FACS)

Klon: CG4

Produktdetails anti-GPR56 Antikörper (PE-Cy7)

Aufreinigung: The antibody was purified by affinity chromatography and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu GPR56

Target: GPR56 (G Protein-Coupled Receptor 56 (GPR56))

Andere Bezeichnung: GPR56

Hintergrund: GPR56, also known as TM7XN1, is an orphan G-protein-coupled receptor (GPCR) containing seven transmembrane domains and a mucin-like domain in the N-terminal region. The total length of the human GPR56 gene is approximately 15 kb, and it consists of 13 exons and encodes 693 amino acids. GPR56 is expressed in a wide range of tissues, such as brain, thyroid gland, and heart. Mutations in human GPR56 gene were found to cause a specific brain malformation called bilateral frontoparietal polymicrogyria. Recently, GPR56 was found specifically expressed on cytotoxic NK and T lymphocytes, including CD8+, CD4+, and γδ T cells, which might affect the migratory properties of these cells. GPR56 was also found significantly downregulated in some cancer cells, suggesting that it may play a role in growth suppression and cancer metastasis.